Cardiotoxicity of Non-Cardiovascular Drugs

Preface. List of Contributors. Abbreviations. . 1. Mitochondrial Dysfunction In Cell Injury and Cardiotoxicity (Fabio Di Lisa, Martina Semenzato, Andrea Carpi, Sara Menazza, Nina Kaludercic, Roberta Menabo, Marcella Canton). 2. Cardiovascular Liabilities of Drugs: Regulatory Aspects (Claudio Arrigoni). 3. Cellular Mechanisms, Molecular Targets, and Structure-Function Relationships In Drug-Induced Arrhythmias: The Case Of Antihistamines, Psychoactive Drugs, and Antimicrobial Agents (Maria Virginia Soldovieri and Maurizio Taglialatela). 4. Cardiovascular Toxicity of Antitumor Drugs: Dimensions of the Problem in Children (Rebecca Scully, Louis Pruitt, Steven E. Lipshultz). 5. Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings (Joseph R. Carver and Chaitali J. Desai). 6. Diagnostic Aspects of Cardiovascular Toxicity of Antitumor Drugs (Michael S. Ewer, Thomas M. Suter). 7. Cardiovascular Toxicity of Antitumor Drugs: Translating Molecular Mechanisms into Clinical Facts (Pierantonio Menna, Emanuela Salvatorelli, Carlo Salsano, Luca Gianni, and Giorgio Minotti). 8. NSAID Action and the Foundations for Cardiovascular Toxicity (Anna L. Blobaum and Lawrence J. Marnett). 9. Cardiovascular toxicities of NSAIDS: Epidemiologic aspects (Antonio Gonzalez-Perez, Luis Alberto Garcia Rodriguez). 10. Cardiovascular Toxicities of Life-Saving Drugs: Antiviral Therapy (James J. Kohler & William Lewis). Index.

[1]  P. Russo.  Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma , 2009 .

[2]  R. Slavin,et al.  Marrow transplanation in man following cyclophosphamide. , 1971, Transplantation proceedings.

[3]  G. Brittinger,et al.  CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Zidek,et al.  Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. , 1993, Cardiovascular research.

[6]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Ross,et al.  Acute arrhythmogenicity of doxorubicin administration , 1987, Cancer.

[8]  M. Ghielmini,et al.  A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function , 2008, Clinical Cancer Research.

[9]  C. V. Strihou,et al.  Hypertension after renal transplantation. , 1976, British medical journal.

[10]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[11]  A. Chan,et al.  A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  G. Scagliotti,et al.  Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Christian,et al.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Conrad.  Cytarabine and Cardiac Failure , 1992, American journal of hematology.

[15]  Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. , 2001 .

[16]  D. Porter,et al.  Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation , 2005, Leukemia & lymphoma.

[17]  V. Valero,et al.  Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  P. Philip,et al.  Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. C. Viswanathan,et al.  New Mechanism Contributing to Drug-Induced Arrhythmia: Rescue of a Misprocessed LQT3 Mutant , 2005, Circulation.

[20]  A. Dalgleish,et al.  Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Dizon,et al.  Dyspnea during Thalidomide Treatment for Advanced Ovarian Cancer , 2005, The Annals of pharmacotherapy.

[22]  E. Winer,et al.  Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Häussinger,et al.  Cardiotoxicity of the Antiprolif erative Compound Fluorouracil , 1999, Drugs.

[24]  W. Hait,et al.  Tubulin-targeting agents. , 2003, Cancer chemotherapy and biological response modifiers.

[25]  M. Blute.  Sunitinib in patients with metastatic renal cell carcinoma , 2006 .

[26]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[27]  A. Ferrant,et al.  Pericarditis induced by high-dose cytosine arabinoside chemotherapy , 1997, Annals of Hematology.

[28]  B. Jensen,et al.  Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  H. White,et al.  A case of cardiogenic shock caused by capecitabine treatment , 2008, Nature Clinical Practice Cardiovascular Medicine.

[30]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Y. Goldsmith,et al.  Capecitabine-induced coronary vasospasm. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Shyu.  Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure? , 2008, Circulation research.

[33]  K. Kolaja,et al.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes , 2011, Nature Reviews Drug Discovery.

[34]  F. Appelbaum,et al.  Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. , 1990, Bone marrow transplantation.

[35]  J. Baselga,et al.  Targeting the microtubules in breast cancer beyond taxanes: the epothilones. , 2007, The oncologist.

[36]  A. Castaigne,et al.  MYOCARDIAL INFARCTION FOLLOWING VINBLASTINE TREATMENT , 1980, The Lancet.

[37]  K. Nugent,et al.  Acute Cardiac Toxicity Associated with High‐Dose Intravenous Methotrexate Therapy: Case Report and Review of the Literature , 2005, Pharmacotherapy.

[38]  D. Neuberg,et al.  Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Talpaz,et al.  Vindesine-associated angina and ECG changes. , 1982, Cancer treatment reports.

[40]  P. Venugopal,et al.  Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. , 2001, Blood.

[41]  D P Dearnaley,et al.  Cardiovascular disease as a long-term complication of treatment for testicular cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  P. Dombernowsky,et al.  Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Zaletel,et al.  Thrombosis of Internal Carotid Artery after Cisplatin-Based Chemotherapy , 2006, European Neurology.

[44]  D. Kuhn,et al.  Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade , 2008, Clinical Cancer Research.

[45]  G. Hortobagyi,et al.  A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  T. Cerny,et al.  Acute Pericarditis and Pleural Effusion Complicating Cytarabine Chemotherapy , 2003, Oncology Research and Treatment.

[47]  K. Ness,et al.  High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation , 2009, Bone Marrow Transplantation.

[48]  C. Becerra,et al.  Adverse effects of bevacizumab and their management in solid tumors. , 2006, Supportive cancer therapy.

[49]  H. Caron,et al.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.

[50]  G. Salles,et al.  Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  S. Horning,et al.  Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R. Karaoǧuz,et al.  Severe vascular toxicity associated with cisplatin‐based chemotherapy , 1993, Cancer.

[53]  A. Zander,et al.  Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation , 2008, Haematologica.

[54]  Y. Kanda,et al.  Predictors for severe cardiac complications after hematopoietic stem cell transplantation , 2004, Bone Marrow Transplantation.

[55]  W. Hahn,et al.  Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes , 2004, Clinical Cancer Research.

[56]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[57]  Liu,et al.  Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway , 2009, Circulation.

[58]  R. Herbst,et al.  Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  A. Frustaci,et al.  Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience. , 2008, Leukemia research.

[60]  J. Thigpen.  Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study , 2009 .

[61]  C. Begg,et al.  High-dose ifosfamide with mesna uroprotection: a phase I study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  R. Pazdur,et al.  FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. , 2003, The oncologist.

[63]  Narine Sarvazyan,et al.  Anthracycline cardiotoxicity: from bench to bedside. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  M. Goldberg,et al.  Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. , 1986, Blood.

[65]  Richard J Stephens,et al.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  B. Cheson,et al.  Lenalidomide for the treatment of B-cell malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Yeon-Hee Park,et al.  BNP as a marker of the heart failure in the treatment of imatinib mesylate. , 2006, Cancer letters.

[68]  A. Alencar,et al.  Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. , 2004, Blood.

[69]  S. Rosenberg,et al.  Cardiopulmonary toxicity of treatment with high dose interleukin‐2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma , 1994, Cancer.

[70]  J. Friedberg,et al.  Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  E. Winer,et al.  Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  D. Wallwiener,et al.  Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. , 2004, European journal of cancer.

[73]  G. Silverman,et al.  Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. , 2003, Arthritis and rheumatism.

[74]  G. Peters,et al.  A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[75]  L. Kritharides,et al.  Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function , 2007, Heart.

[76]  R. Maki,et al.  Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  A Messori,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[78]  Robert B. Diasio,et al.  Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.

[79]  M. Clausen,et al.  Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  L. Gianni,et al.  Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  S. Topal,et al.  Gemcitabine-Induced Acute Coronary Syndrome: A Case Report , 2008, Medical Principles and Practice.

[82]  R. Abonour,et al.  Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. , 2006, Clinical lymphoma & myeloma.

[83]  Susumu Minamisawa,et al.  ErbB2 is essential in the prevention of dilated cardiomyopathy , 2002, Nature Medicine.

[84]  J. Shuster,et al.  Results of a Randomized Phase III Trial in Children and Adolescents with Advanced Stage Diffuse Large Cell Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Study , 2002, Leukemia & lymphoma.

[85]  M. Suntharalingam,et al.  Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. , 2008, International journal of radiation oncology, biology, physics.

[86]  Jon Sharp,et al.  Late congestive heart failure after hematopoietic cell transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  U. Pelzer.  Second-line chemotherapy in advanced pancreatic cancer. , 2008, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[89]  T. Robak,et al.  Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  S. Singhal,et al.  Thalidomide in cancer: potential uses and limitations. , 2001, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[91]  M. Pestrin,et al.  Taxanes in the elderly: can we gain as much and be less toxic? , 2009, Critical reviews in oncology/hematology.

[92]  M. Wong.  The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics , 2008, Current oncology reports.

[93]  V. Zadnik,et al.  Cardiac Toxicity of High-Dose Cyclophosphamide in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation , 2007, International journal of hematology.

[94]  Atrial Fibrillation Induced by Gemcitabine Treatment in a 65-Year-Old Man , 2007, Oncology Research and Treatment.

[95]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  J. Forbes,et al.  BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC) , 2007 .

[97]  A. Smit,et al.  Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  J Shaughnessy,et al.  Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. , 2001, Blood.

[99]  C. Sessa,et al.  Ongoing phase I and II studies of novel anthracyclines , 2007, Cardiovascular Toxicology.

[100]  R. Pazdur,et al.  Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[101]  Haiyi Jiang,et al.  Overview of gefitinib in non-small cell lung cancer: an Asian perspective. , 2008, Japanese journal of clinical oncology.

[102]  M. Gordon,et al.  Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma , 2009 .

[103]  J. Kirkwood,et al.  Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma , 2008, Cancer.

[104]  Orciuolo Enrico,et al.  Unexpected cardiotoxicity in haematological bortezomib treated patients. , 2007, British journal of haematology.

[105]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[106]  Y. Ramot,et al.  Drug-Induced Thrombosis—Experimental, Clinical, and Mechanistic Considerations , 2007, Toxicologic pathology.

[107]  M. Gordon.  Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma , 2006 .

[108]  W. Dahut,et al.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[109]  S. Lipsitz,et al.  Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  M. Mazumdar,et al.  Arsenic trioxide and low‐dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia , 2008, Cancer.

[111]  H. Kantarjian,et al.  Congestive heart failure is a rare event in patients receiving imatinib therapy. , 2006, Blood.

[112]  M. Vassilomanolakis,et al.  Ifosfamide cardiotoxicity in humans , 2004, Cancer Chemotherapy and Pharmacology.

[113]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  S. Palmer,et al.  Cardiovascular risk in long‐term survivors of testicular cancer , 2008, Cancer.

[115]  J. Irani.  [Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma]. , 2007, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[116]  A. Baumelou,et al.  Acute cardiac and renal failure after 5-FU and cisplatin treatment. , 1991, Nephron.

[117]  N. Geller,et al.  A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  F. Ognibene,et al.  High-Dose Ifosfamide Is Associated with Severe, Reversible Cardiac Dysfunction , 1993, Annals of Internal Medicine.

[119]  J. Armitage,et al.  Acute coronary syndromes complicating the first infusion of rituximab. , 2008, Clinical lymphoma & myeloma.

[120]  S. Allerheiligen,et al.  Preclinical, pharmacologic, and phase I studies of gemcitabine. , 1997, Seminars in oncology.

[121]  M. Lader,et al.  Cardiovascular effects of antidepressants , 1990, Psychological medicine. Monograph supplement.

[122]  T. Younis.  Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma , 2003, British journal of haematology.

[123]  Y. Ko,et al.  Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[124]  T. Vial,et al.  Immune-mediated side-effects of cytokines in humans. , 1995, Toxicology.

[125]  K. Schultz,et al.  Cardiac manifestations of graft-versus-host disease. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[126]  H. Choy,et al.  Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue , 2008, Clinical Cancer Research.

[127]  Y. Martinet,et al.  Cisplatin-induced atrial fibrillation. , 1991, Journal of Clinical Oncology.

[128]  T. Tabei,et al.  Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. , 2005, Japanese journal of clinical oncology.

[129]  José Manuel Cervera Grau,et al.  Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin’s diffuse large B-cell lymphoma , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[130]  N. Hanna.  Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial , 2008 .

[131]  M. Mori,et al.  How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  Patrick F. Smith,et al.  Gemcitabine and Acute Myocardial Infarction , 2006, Angiology.

[134]  A. Hacıhanefioğlu,et al.  Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib , 2008, International journal of hematology.

[135]  F. Ognibene,et al.  Cardiorespiratory effects of immunotherapy with interleukin-2. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  S. De Flora,et al.  Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention , 2010, Journal of the National Cancer Institute.

[137]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[138]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  Shenhong Wu,et al.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.

[140]  S. Cosimo,et al.  A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER 2 expression : changing the natural history of HER 2-positive disease , 2006 .

[141]  O. Hermine,et al.  Severe cardiac toxicity after monoclonal antibody therapy , 2002, European journal of haematology.

[142]  K. Brunner,et al.  Neurologic and cardiac toxicity following iv application of methotrexate. , 1982, Cancer treatment reports.

[143]  J. Forbes,et al.  Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  K. Woodside,et al.  Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[145]  T. Xu,et al.  Cyclophosphamide‐evoked heart failure involves pronounced co‐suppression of cytoplasmic thioredoxin reductase activity and non‐protein free thiol level , 2009, European journal of heart failure.

[146]  A. Camm,et al.  Drug induced QT prolongation and torsades de pointes , 2003, Heart.

[147]  Maurizio Recanatini,et al.  Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes , 2002, Drug safety.

[148]  J. Forbes,et al.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  A. Ribeiro,et al.  An evaluation of the cardiotoxicity of imatinib mesylate. , 2008, Leukemia research.

[150]  P. Steinherz,et al.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.

[151]  R. Riccardi,et al.  Anthracycline-related cardiotoxicity: risk factors and therapeutic options in childhood cancers , 2008 .

[152]  R. Ohno,et al.  Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia , 2000, Annals of Internal Medicine.

[153]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[154]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[155]  T. Kuzel,et al.  Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma , 2007, Cancer.

[156]  J. Jassem,et al.  Evaluation of trastuzumab (Herceptin®), docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer , 2007 .

[157]  S. Hirschfeld,et al.  FDA drug approval summaries: oxaliplatin. , 2004, The oncologist.

[158]  Greg Yothers,et al.  Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  C. Tournigand,et al.  [Cardiotoxicity of 5-fluorouracil]. , 2004, Bulletin du cancer.

[160]  Z. Sasson,et al.  5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. , 1994, The Canadian journal of cardiology.

[161]  P. Rochaix,et al.  Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin , 2008, Clinical Cancer Research.

[162]  U. Hofmann,et al.  Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  G. Batist,et al.  Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  J. Nabholtz.  Long-term safety of aromatase inhibitors in the treatment of breast cancer , 2008, Therapeutics and clinical risk management.

[165]  R. Diasio,et al.  Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. , 1988, The Journal of clinical investigation.

[166]  C. Kuropkat,et al.  Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. , 1999, American journal of clinical oncology.

[167]  N. Hanna,et al.  Vinorelbine Plus Cisplatin vs Observation in Resected Non–Small-Cell Lung Cancer , 2006 .

[168]  D. Weisdorf,et al.  Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997 , 2001, Bone Marrow Transplantation.

[169]  M. Dyer,et al.  No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. , 2005, Blood.

[170]  J. Cuzick,et al.  Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. , 2006, The Lancet. Oncology.

[171]  S. Bhatia,et al.  Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation , 2008, British journal of haematology.

[172]  J. Baynes,et al.  The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. , 2006, Biochimica et biophysica acta.

[173]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[174]  Han‐Chung Wu,et al.  Anti-Angiogenic Therapeutic Drugs for Treatment of Human Cancer , 2008 .

[175]  D. G. Wenzel.  Drug-induced cardiomyopathies. , 1967, Journal of pharmaceutical sciences.

[176]  J. Gottdiener,et al.  Cardiotoxicity associated with high-dose cyclophosphamide therapy. , 1981, Archives of internal medicine.

[177]  J. Dalzell,et al.  The spectrum of 5-fluorouracil cardiotoxicity , 2009, Anti-cancer drugs.

[178]  S. Soignet,et al.  Effect of arsenic trioxide on QT interval in patients with advanced malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  A. Burnett,et al.  Chemotherapy‐induced cardiotoxicity: current practice and prospects of prophylaxis , 2002, European journal of heart failure.

[180]  K. Hirata,et al.  Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer , 2008, Journal of Translational Medicine.

[181]  Y. Lee,et al.  Complete Atrioventricular Block after Arsenic Trioxide Treatment in an Acute Promyelocytic Leukemic Patient , 1999, Pacing and clinical electrophysiology : PACE.

[182]  K. Hess,et al.  Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  M. Somerfield,et al.  American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  P. Lønning,et al.  Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.

[185]  J. Reckelhoff.  Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. , 2005, Hypertension.

[186]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[187]  R. Kurzrock,et al.  Phase II study of alemtuzumab in chronic lymphoproliferative disorders , 2003, Cancer.

[188]  I. Filipović,et al.  Capecitabine cardiotoxicity--case reports and literature review. , 2008, Hepato-gastroenterology.

[189]  D. Vaughn,et al.  Cardiovascular late effects and the ongoing care of adult cancer survivors. , 2008, Disease management : DM.

[190]  P. Campochiaro,et al.  A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. , 2006, Ophthalmology.

[191]  F. Shepherd,et al.  Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer , 2007 .

[192]  M. Sonnenblick,et al.  Cardiotoxicity of interferon. A review of 44 cases. , 1991, Chest.

[193]  J. Grygiel,et al.  Hypercholesterolemia after chemotherapy for testis cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[194]  J. Bourhis,et al.  Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[195]  S. Colan,et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[196]  R. Diasio,et al.  Predicting fluorouracil toxicity: can we finally do it? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[197]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[198]  N. Robert,et al.  Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[199]  O. Press.  Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  J. Berenson,et al.  A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma , 2007, Clinical Cancer Research.

[201]  M. Chen,et al.  Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics , 2008, Circulation.

[202]  J. Feliu,et al.  Cardiac toxicity: old and new issues in anti-cancer drugs , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[203]  C. Hudis,et al.  Tolerance of bevacizumab in an older patient population: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience , 2008 .

[204]  A. Eisen,et al.  Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. , 2008, Cancer treatment reviews.

[205]  David Zurakowski,et al.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.

[206]  D. Lake,et al.  The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[207]  S. Swain,et al.  The Epothilones: Translating from the Laboratory to the Clinic , 2008, Clinical Cancer Research.

[208]  M. Lapeyre-Mestre,et al.  Vinorelbine‐related cardiac events: a meta‐analysis of randomized clinical trials , 2004, Fundamental & clinical pharmacology.

[209]  P. Sevelda,et al.  Thrombosis with paclitaxel , 1994, The Lancet.

[210]  S. Martino,et al.  Reversible arrhythmias observed in patients treated with recombinant alpha2 interferon , 2004, Journal of Cancer Research and Clinical Oncology.

[211]  N. Vogelzang,et al.  Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin , 1985, Cancer.

[212]  C. Hawkey,et al.  Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors , 2003, Gut.

[213]  J. Byrd,et al.  Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia , 2007, Oncogene.

[214]  D. Roden.  Pharmacogenetics and drug-induced arrhythmias. , 2001, Cardiovascular research.

[215]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[216]  K. Shen,et al.  Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .

[217]  L. Seymour,et al.  Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[219]  G. Bonadonna,et al.  Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[220]  J. Koeller,et al.  Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists , 2003, The Annals of pharmacotherapy.

[221]  X. Thomas,et al.  Gemtuzumab Ozogamicin (Mylotarg®) as Single Agent Treatment for Adult Patients with Acute Myeloid Leukemia (AML). , 2005 .

[222]  T. Ley,et al.  Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. , 2001, Blood.

[223]  A. Davies,et al.  Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. , 2008, The oncologist.

[224]  A. Gemma,et al.  First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[225]  A. Kudelka,et al.  Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. , 2008, The Lancet. Oncology.

[226]  P. Quaglino,et al.  Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. , 2007, Haematologica.

[227]  B. Schnetzler,et al.  Coronary spasm induced by capecitabine. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[228]  G. Wood,et al.  Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. , 2001, Archives of dermatology.

[229]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[230]  B. Barlogie,et al.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.

[231]  H. Wieand,et al.  Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[232]  M. Halushka,et al.  Heart failure associated with sunitinib malate , 2008, Cancer.

[233]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[234]  S. Srinivas,et al.  Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate , 2008 .

[235]  M. Štěrba,et al.  Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron , 2009, Pharmacological reports : PR.

[236]  Janice M. Lu,et al.  Novel therapies in breast cancer: what is new from ASCO 2008 , 2008, Journal of hematology & oncology.

[237]  F. Romano,et al.  Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients , 2008, Langenbeck's Archives of Surgery.

[238]  D. Keefe.  The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? , 2002, The oncologist.

[239]  J. Bergh,et al.  Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[240]  C. Papadopoulos,et al.  Capecitabine-associated coronary vasospasm: a case report , 2008, Emergency Medicine Journal.

[241]  P. Bhargava.  VEGF kinase inhibitors: how do they cause hypertension? , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

[242]  G. Lip,et al.  Assessment of endothelial damage and dysfunction: observations in relation to heart failure. , 2003, QJM : monthly journal of the Association of Physicians.

[243]  B. Vincenzi,et al.  Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[244]  D. Dodwell,et al.  Etoposide-related myocardial infarction. , 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

[245]  P. Salem,et al.  Supraventricular tachycardia. A probable complication of platinum treatment. , 1984, Oncology.

[246]  D. Qian,et al.  Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias , 2004, Clinical Cancer Research.

[247]  D. Richel,et al.  Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[248]  B. Barlogie,et al.  Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. , 2002, Blood.

[249]  K. Gelmon,et al.  The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines , 2008, Breast Cancer Research and Treatment.

[250]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[251]  D. Ferrari,et al.  Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity. , 2006, Anti-cancer drugs.

[252]  M. Kris,et al.  Gemcitabine-Induced Peripheral Edema: Report on 15 Cases and Review of the Literature , 2003, American journal of clinical oncology.

[253]  J. Robert,et al.  Results of a phase I study of DTS-201, a peptidic prodrug of doxorubicin, in patients with solid tumors , 2007 .

[254]  S. Steinberg,et al.  Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma , 2006, Clinical Cancer Research.

[255]  R. Pazdur,et al.  FDA drug approval summary: erlotinib (Tarceva) tablets. , 2005, The oncologist.

[256]  R. Pazdur,et al.  Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies Report from the Fda , 2022 .

[257]  M. Duvic,et al.  Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[258]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[259]  Nosheen Fatima.  CARDIOTOXICITY OF ANTICANCER DRUGS , 2009 .

[260]  F. Kabbinavar,et al.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.

[261]  J. Steinberger,et al.  Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. , 2005, Blood.

[262]  D. Keefe,et al.  Clinical Cardiotoxicity of 5‐Fluorouracil , 1993, Journal of clinical pharmacology.

[263]  J. O’Shaughnessy,et al.  Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. , 2002, Clinical breast cancer.

[264]  M. Poulsen,et al.  Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[265]  Jean-Pierre Valentin,et al.  Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. , 2009, American heart journal.

[266]  M. Ro̸rth,et al.  Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[267]  E. Shpall,et al.  Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[268]  I. Çelik,et al.  Recurrent Asymptomatic Bradycardia Episodes after Cisplatin Infusion , 2001, The Annals of pharmacotherapy.

[269]  S. Cha,et al.  Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[270]  M. Mego,et al.  Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[271]  M. Trudeau,et al.  Gemcitabine in the management of metastatic breast cancer: a systematic review , 2008, Breast Cancer Research and Treatment.

[272]  P. Kouides,et al.  Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. , 1995, Leukemia research.

[273]  A. Gratwohl,et al.  Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. , 2007, Blood.

[274]  Hannes Kaufmann,et al.  Thromboembolic events during treatment with thalidomide. , 2002, Blood.

[275]  M. Boccadoro,et al.  Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[276]  K. Friedrichs,et al.  Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[277]  F. Dentali,et al.  Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura , 2007, Annals of Internal Medicine.

[278]  M. Dimopoulos,et al.  Adverse effects of thalidomide administration in patients with neoplastic diseases. , 2004, The American journal of medicine.

[279]  K. Zervas,et al.  Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[280]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[281]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[282]  B. Leber,et al.  Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[283]  T. Shepard.  Catalog of Teratogenic Agents , 1973 .

[284]  D. Thiele,et al.  Sudden death during doxorubicin administration , 1979, Cancer.

[285]  Chiara Benedetto,et al.  Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[286]  P. Conte,et al.  Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. , 2009, International journal of radiation oncology, biology, physics.

[287]  Bruce D Cheson,et al.  Bendamustine: rebirth of an old drug. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[288]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[289]  Bruce D Cheson,et al.  Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. , 2008, The New England journal of medicine.

[290]  L. Vaickus,et al.  Pericarditis induced by high-dose cytarabine therapy. , 1984, Archives of internal medicine.

[291]  D. Sebag‐Montefiore,et al.  Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[292]  J. Crowley,et al.  Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[293]  G. Bonadonna,et al.  Phase II evaluation of adriamycin in human neoplasia , 1973, Cancer.

[294]  A. Wåhlin,et al.  Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia , 2004, Cancer Chemotherapy and Pharmacology.

[295]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[296]  R. Nesto,et al.  Recombinant alpha 2 interferon-related cardiomyopathy. , 1988, The American journal of medicine.

[297]  M. Elisaf,et al.  Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. , 2001, European journal of cancer.

[298]  J. Whitworth,et al.  Pressor responsiveness in corticosteroid-induced hypertension in humans. , 1992, Hypertension.

[299]  J. Baselga,et al.  Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy , 2005, Clinical Cancer Research.

[300]  K. Höffken,et al.  Severe non-haematological toxicity after treatment with gemcitabine , 1999, Journal of Cancer Research and Clinical Oncology.

[301]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[302]  M. Djaldetti,et al.  Vincristine‐induced myocardial infarction , 1975, Cancer.

[303]  M. Campone,et al.  Vinflunine: A New Microtubule Inhibitor Agent , 2008, Clinical Cancer Research.

[304]  H. Sørensen,et al.  Tamoxifen Treatment in Danish Breast Cancer Patients and 5-Year Risk of Arterial Atherosclerotic Events: A Null Association , 2008, Cancer Epidemiology Biomarkers & Prevention.

[305]  Jm Dippenaar,et al.  Local anaesthetic toxicity , 2007 .

[306]  M. Grever,et al.  Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors , 2006, Clinical Cancer Research.

[307]  I. Bernstein,et al.  Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.

[308]  E. Perez,et al.  Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. , 2008, Mayo Clinic proceedings.